Condition
Pleural Mesothelioma|Malignant Pleural Mesothelioma
Estimated Enrollment: 70
Age Group: 18 Years and older (Adult, Senior)
Gender: All
Study Type: Interventional
Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment
Study ID Numbers: 99-124
Study First Received: September 12, 2005
Last Updated: March 26, 2014
Estimated Primary Completion Date: April 2002
Primary Outcome Measures:
To determine the maximally tolerated dose of intracavitary cisplatin in patients with malignant pleural mesothelioma,|To quantitate the safety of intraoperative intrathoracic/intraperitoneal hyperthermic cisplatin|to study the pharmacokinetics of cisplatin administered in this way.
Sponsors and Collaborators:
Dana-Farber Cancer Institute|Brigham and Women’s Hospital
Website Link: https://ClinicalTrials.gov/show/NCT00165555
